摘要
原发性肺淋巴上皮瘤样癌(LELC)是一类独特且少见的肺恶性肿瘤,发病率不足非小细胞肺癌的1%。然而该病在我国华南地区及东南亚国家却相对常见,患者发病年龄相对年轻,与性别及吸烟史无关。与高加索人不同,亚裔人群中肺LELC与EB病毒感染密切相关。组织病理学上,肺LELC与未分化鼻咽癌难以区分,因此诊断肺LELC需要排除鼻咽癌肺转移。手术、放疗及化疗仍然是肺LELC的主要治疗手段。靶向治疗现已成为治疗驱动基因阳性非小细胞肺癌的重要手段,但目前尚未发现肺LELC的驱动基因。近年来,免疫治疗在包括肺癌在内的多种恶性肿瘤的研究中取得重要进展,但在肺LELC中尚缺少系统的报道。与经典的非小细胞肺癌相比,原发性肺LELC的流行病学、临床病理特征、诊断治疗及预后均有所不同,本文将就肺LELC的研究进展进行综述。
Primary pulmonary lymphoepithelioma-Iike carcinoma (LELC)is a distinct and rare tumor.The incidence of this disease is less than 1percent of the incidence of non small cell lung cancer (NSCLC).LELC is relatively common in south China and South-East Asia.Patients with this disease are relatively young.LELC has no significant association with gender and history of smoking.However,it is closely related to EB virus infection in Asian while it is rarely seen in Cauca- sian.For its diagnosis,the exclusion of lung metastases from nasopharyngeal cancer from LELC is mandatory because it is difficult to distinguish undifferentiated nasopharyngeal carcinoma from LELC histopathologically.Surgery,chemotherapy and radiotherapy are still major therapeutic strategies for LELC.Targeted therapy has become an important method in treating ad- vanced NSCLC with positive gene mutations.Unfortunately,no driver gene has been found in LELC until now.Although im- munotherapy has made great advances in various malignant carcinomas including NSCLC,there is scarce literature of immu- notherapy for LELC.This disease is different from NSCLC in epidemiology,clinicopathologie features,diagnosis,therapy and prognosis.We reviewed the progress in diagnosis and treatment of LELC.
作者
陈思林
胡欣
Chen Silin;Hu Xin(Oncology Center,The Second Clinical Medic'al College of North Sichuan Medical College,Nanchong Central Hospital,Nanchong 637000,Sichuan,China)
出处
《肿瘤预防与治疗》
2018年第6期444-448,共5页
Journal of Cancer Control And Treatment
